PARP1 and ovarian carcinoma: Moreover, treatment of ovarian cancer models with PARP inhibitors in vitro resulted in no decrease in the viability of the cancer stem cell population, and this effect was demonstrated independent of BRCA status, suggesting an HR-independent mechanism of resistance [123].